Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-27

Study Completion Date

2017-01-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India:

Primary objective:

* To describe in each age group the immune response induced by a single injection (participants aged \>9 years) or 2 injections (participants aged 6 months to 8 years) of QIV.

Secondary objective:

* To describe in each age group the safety profile of QIV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

NCT01481454

Influenza

COMPLETED PHASE3

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343

Influenza

COMPLETED PHASE2

A Study of Influenza Virus Vaccines in Children and Adults

NCT00988143

Influenza

COMPLETED PHASE2

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

NCT01967784

Influenza

COMPLETED PHASE3

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

NCT04101435

Influenza

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All participants were vaccinated with the QIV (split-virion, inactivated) Northern Hemisphere (NH) or Southern Hemisphere (SH) formulations by the intramuscular (IM) route. Immunogenicity of the vaccine was assessed at baseline (Day 0) and 28 days after the last injection. Safety data were collected up to 28 days after each injection. Serious adverse events (SAEs) were collected throughout the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months

Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.

Group Type EXPERIMENTAL

Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative

Intervention Type BIOLOGICAL

0.25 mL, Intramuscular

Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years

Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.

Group Type EXPERIMENTAL

Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years

Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.

Group Type EXPERIMENTAL

Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Quadrivalent Influenza Vaccine Group 4: >=18 Years

Participants aged \>=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.

Group Type EXPERIMENTAL

Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative

0.25 mL, Intramuscular

Intervention Type BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

QIV, No Preservative QIV, No Preservative QIV, No Preservative QIV, No Preservative

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 6 months or older on the day of inclusion
* For participants aged 6 to 35 months only: born at full term of pregnancy (\>=37 weeks) or birth weight \>=2.5 kg or both
* Informed consent form had been signed and dated by the participants / participants' parent(s) or another legally acceptable representative and by an independent witness, if required by local regulations. For participants aged 7 to 17 years of age, assent form has been signed and dated by the participants
* Participants / participants' parent/legally acceptable representative were able to attend all scheduled visits and to comply with all trial procedures

Exclusion Criteria

* For participants aged 9 years or older only: participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)
* Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks following any trial vaccination (except Oral Poliomyelitis Vaccine (OPV) received during national immunization days)
* For participants aged 9 years or older only: previous vaccination against influenza (in the previous 9 months) with any influenza vaccine
* For participants aged 6 months to 8 years only: previous priming with any influenza vaccine (i.e., participants who received 2 doses for at least 1 previous influenza season)
* Receipt of immune globulins, blood or blood-derived products in the past 3 months
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
* Self-reported history of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, after questioning
* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
* Self-reported thrombocytopenia or as reported by the parent/legally acceptable representative, contraindicating intramuscular vaccination
* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
* For participants aged 9 years or older only: current alcohol abuse or drug addiction
* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion
* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (axillary temperature \>=38.0 degree Celsius). A prospective participants should not be included in the study until the condition had resolved or the febrile event has subsided
* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes